Drug intelligence / Profile preview

MOMA Therapeutics undisclosed GTPase inhibitor

Development stage: Preclinical
Lead developer: MOMA Therapeutics
Modality: Small Molecules

Overview

MOMA Therapeutics is developing a small molecule inhibitor targeting an undisclosed GTPase for the treatment of cancer. This program is part of MOMA's focus on 'molecular machines'—enzymes such as ATPases and GTPases that undergo significant conformational changes to perform work within the cell. By utilizing a platform that characterizes these dynamic protein states, MOMA aims to identify novel binding pockets and develop highly selective small molecules for targets that have been challenging to drug using traditional methods. The program is currently in the discovery stage.

Beyond the preview

Go deeper on MOMA Therapeutics undisclosed GTPase inhibitor.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on MOMA Therapeutics undisclosed GTPase inhibitor.

Explore the full profile